All In Biotech

Drug Trial Radar · NCT05498766

Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients

Effect and Safety of Huaier Granule Versus SOX Regimen for the Prevention of Recurrence/Metastasis After Radical Surgery for Stage II-III Gastric Cancer Patients: a Prospective, Multi-center, Open-label and Randomised Control Study

Last checked: Nov 19, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 702 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

702

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Jul 1, 2029

Study completion Nov 1, 2029

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
LinkDoc Technology (Beijing) Co. Ltd.
First posted
Aug 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, open-label, randomised controlled study. The purpose of this study is to evaluate the efficacy and safety of Huaier Granule versus SOX regimen in the postoperative adjuvant treatment of resectable stage II-III gastric cancer.

Conditions

  • Gastric Cancer

Interventions

  • Huaier granuleDrug

    Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.

  • OxaliplatinDrug

    Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.

  • Tegafur, Gimeracil and Oteracil PotassiumDrug

    Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year DFS rateTime frame: up to 36-months follow-up

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Wuhan Union Hospital

    Wuhan, Hubei, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.